All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
In particular, management highlighted growth in Repatha and Evenity, which delivered 45% and 36% growth even as they have reached 2024 sales of $2.22B and $1.56B respectively. Among Amgen's top ...
Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...
The adjustments related primarily to noncash amortization of intangible assets and fair value step-up of inventory acquired from business acquisitions.
Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
Prolia (osteoporosis) and Xgeva (fracture prevention in cancer patients) saw $6.6 billion in combined sales in 2024 but look vulnerable to biosimilars in 2025. To address these headwinds ...
Why it matters: Amgen's performance in 2024 was in line with our estimates ... Research and development expenses are growing faster than sales, but other operating expense cost controls from ...
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...